Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis
Article 2013 en
Authors
HH
Hans Hartung
LS
Lawrence Steinman
DG
Douglas S. Goodin
Abstract
1 min read
An increase of IL-17F before and early after treatment with interferon beta-1b was not associated with poor response. These data do not support the value of IL-17F as a treatment response indicator for therapy of patients with multiple sclerosis with interferon beta, although high levels of IL-17F greater than 200 pg/mL may predict nonresponsiveness.
Hans-Peter Hartung, Ludwig Kappos, Douglas S. Goodin, Paul O’Connor, Massimo Filippi, Barry G.W. Arnason, Giancarlo Comi, Stuart D. Cook, Douglas Jeffery, John Petkau, Richard White, Timon Bogumil, K. Beckmann, Brigitte Stemper, Gustavo Cruz, Rupert Sandbrink, Christoph Pohl
P. D. Molyneux, Ludwig Kappos, Chris H. Polman, Carlo Pozzilli, Frederik Barkhof, Massimo Filippi, Tarek Yousry, David W. Hahn, Klaus Wagner, Mahdiyeh Khabbaz Koche Ghazi, K. Beckmann, Frank Dahlke, Nicholas Losseff, Gareth J. Barker, Alan J. Thompson, D. H. Miller
Kathryn C. Fitzgerald, Kassandra L. Munger, Karl Köchert, Barry G.W. Arnason, Gıancarlo Comı, Stuart D. Cook, Douglas S. Goodin, Massimo Filippi, Hans-Peter Hartung, Douglas Jeffery, Paul O’Connor, Gustavo Cruz, Rupert Sandbrink, Ludwig Kappos, Christoph Pohl, Alberto Ascherio
Ermelinda De Meo, Massimo Filippi, Vincenzo Brescia Morra, Francesco Patti, Giorgia Teresa Maniscalco, Valentina Torri Clerici, Giuseppe Salemi, Marco Onofrj, Giacomo Lus, Marta Simone, María Trojano, Maria Pia Amato
Discussion(0)
No comments yet. Be the first to comment.